31 results
DFAN14A
FUSN
Fusion Pharmaceuticals Inc
19 Mar 24
Additional proxy materials by non-management
5:27pm
.
The combination of our leadership in oncology with Fusion’s deep expertise and extensive capabilities in actinium-based RCs has the potential to redefine … leadership in oncology, with Fusion’s deep expertise and capabilities in actinium-based RCs to accelerate the development of potential new cancer
DEFA14A
FUSN
Fusion Pharmaceuticals Inc
19 Mar 24
Additional proxy soliciting materials
6:25am
radiopharmaceutical R&D, pipeline, manufacturing and actinium-225 supply chain, with AstraZeneca’s leadership in small molecules and biologics
8-K
EX-99.2
FUSN
Fusion Pharmaceuticals Inc
19 Mar 24
Voting and Support Agreement
6:24am
, pipeline, manufacturing and actinium-225 supply chain, with AstraZeneca’s leadership in small molecules and biologics engineering to develop novel
8-K
EX-99.1
nfq2j2r9txj6f
16 Oct 23
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors
4:30pm
8-K
xlg55a p1f0ibik
16 Oct 23
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors
4:30pm
8-K
EX-99.1
j6zil10p
9 Aug 22
Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Clinical Program Updates
7:31am
8-K
EX-99.2
902i0a2qc
9 Jun 22
Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs
7:30am
8-K
EX-99.1
krf1g7bks3gzw
17 Mar 22
Fusion Pharmaceuticals Announces Fourth Quarter
7:30am
8-K
EX-99.1
wqrxpe7z0w
9 Nov 21
Fusion Pharmaceuticals Announces Third Quarter 2021 Financial Results and Clinical Program Update
7:46am
8-K
EX-99.1
mwkwb5u
13 Aug 21
Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D
4:11pm
DEF 14A
l4p2zxodmbrvoa
27 Apr 21
Definitive proxy
4:02pm
8-K
EX-99.1
97mykl
2 Apr 21
Departure of Directors or Certain Officers
8:00am
8-K
EX-99.2
p7o7d
2 Mar 21
Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
9:00am